Trials / Completed
CompletedNCT00291226
Glycine vs Placebo for the Schizophrenia Prodrome
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 13 Years – 35 Years
- Healthy volunteers
- Not accepted
Summary
Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.
Detailed description
A pilot clinical trial comparing glycine to placebo in patients with the schizophrenia prodrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glycine | Glycine 0.4 g/kg bid |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2006-02-13
- Last updated
- 2020-04-02
- Results posted
- 2016-12-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00291226. Inclusion in this directory is not an endorsement.